PANCREATIC DUCTAL ADENOCARCINOMA

This early-phase trial tested a new immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy combines an immune booster with cancer-specific pep…

This large phase III trial studied 546 patients whose pancreatic cancer was removed by surgery. It compared chemotherapy alone versus chemotherapy plus erlotinib, followed by more chemo with or without radiation. The goal was to see if adding erlotinib or radiation helps patients…

This early-phase study tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 adults aged 18-79 took part. The main goal was to track side effects, while…

This study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…

This phase 2 trial tested two standard chemotherapy regimens, Folfirinox and Gemcitabine/nab-paclitaxel, in 150 patients with untreated metastatic pancreatic cancer. The goal was to see which works better and to use lab tests to personalize treatment. The study is complete, and r…

This study tested whether adding an immunotherapy drug (Anti-PD-1) to standard chemotherapy could help people with locally advanced or borderline resectable pancreatic cancer. The trial involved 392 participants and compared the combination treatment to chemotherapy alone. The go…

This study tested a new drug called onvansertib combined with standard chemotherapy for people with advanced pancreatic cancer that had spread. The goal was to see if the combination could shrink tumors or slow the disease. The trial involved 41 adults who had already tried one p…

This study tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The goal was to see if this mix could help patients live longer and control the disease. The t…

This study tested a combination of three drugs (nivolumab, BMS-813160, and GVAX) in 22 people with locally advanced pancreatic cancer who had already received chemotherapy and radiation. The goal was to see if the treatment was safe and could help the immune system better attack …

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if this approach is safe and can help control the disease. 75 patient…

This study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy before and after surgery could help the body fight pancreatic cancer better. It involved 28 people with early-stage, removable pancreatic cancer. The goal was to see i…

This study tested a new type of PET scan called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The scan looks for a protein called FAP on cancer cells. Researchers compared the scan results with tis…

This study tested a new imaging agent (64Cu-DOTA-ECL1i) for PET scans to detect a specific marker (CCR2) on pancreatic cancer cells. The goal was to see if the scan could help doctors choose the right treatment and monitor how well it works. 69 adults with pancreatic cancer parti…

This study looked at 200 people with early-stage pancreatic cancer who had Whipple surgery. Researchers found that some patients developed fatty liver within six months after surgery, which may affect nutrition, blood sugar control, and long-term survival. The goal is to help doc…

This study looked at whether it is safe and possible to grow mini-tumors (organoids) from pancreatic cancer samples in the lab. 60 patients with pancreatic cancer provided tumor tissue during surgery or biopsy. The goal was to see if these organoids could be used to test differen…